Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.65 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.59 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.59 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.58 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.58 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.58 |
| ▸ | STK36 | Q9NRP7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829634 | 1.00 | MAPK14 (0.69) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5116393 | 0.90 | MAPK14 (0.56) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5120273 | 0.90 | MAPK14 (0.57) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5121012 | 0.87 | MAPK14 (0.56) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5115734 | 0.86 | MAPK14 (0.60) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL14014414 | 0.84 | MAPK14 (0.74) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5114375 | 0.84 | MAPK14 (0.58) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL2941680 | 0.84 | MAPK14 (0.52) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL4902177 | 0.83 | MAPK14 (0.48) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL30640251 | 0.83 | BRD4 (0.53) | MAPK14MAPK8MAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945816-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20220106310-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| WO-2011100769-A2 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK8 136/4885MAPK9 162/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK8 136/4885MAPK9 162/4885 |
| US-20220106310-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MAPK9 238/4885 |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK14 4250/4885MAPK8 3523/4885MAPK9 1204/4885 |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MAPK9 238/4885 |
| US-11945816-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MAPK9 238/4885 |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | MAPK14 219/4885MAPK8 231/4885MAPK9 238/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | MAPK14 64/4885MAPK8 3/4885MAPK9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.